Phase II Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Ponatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Filgrastim; Mesna; Methotrexate; Methotrexate; Rituximab; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 08 Feb 2018 Planned End Date changed from 1 Apr 2024 to 1 Feb 2025.
- 08 Feb 2018 Planned primary completion date changed from 1 Apr 2024 to 1 Feb 2024.
- 08 Feb 2018 Status changed from not yet recruiting to recruiting.